Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) – Research analysts at SunTrust Banks issued their FY2022 EPS estimates for shares of Tetraphase Pharmaceuticals in a research note issued on Wednesday. SunTrust Banks analyst E. Nash anticipates that the biopharmaceutical company will post earnings per share of $0.58 for the year. SunTrust Banks currently has a “Buy” rating and a $10.00 target price on the stock.
Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 28th. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, December 5th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. B. Riley began coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, February 12th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, BidaskClub downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $10.39.
Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the third quarter worth approximately $107,000. Brighton Jones LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the third quarter worth approximately $108,000. Voya Investment Management LLC boosted its holdings in shares of Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the period. Virtu KCG Holdings LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth approximately $147,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth approximately $162,000. Institutional investors and hedge funds own 58.28% of the company’s stock.
In related news, Director L Patrick Gage purchased 3,880 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares in the company, valued at approximately $250,776. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2018/02/17/tetraphase-pharmaceuticals-inc-ttph-forecasted-to-post-fy2022-earnings-of-0-58-per-share.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.